SPEVIGO CHMP positive opinion new indications SPEVIGO CHMP positive opinion new indications CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Spiolto® Respimat® Spiolto® Respimat® Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
FDA approval NexGard PLUS for dogs FDA approval NexGard PLUS for dogs Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
commitments to sustainable development commitments to sustainable development On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Vetera Vetera For vaccination of healthy horses as an aid in the prevention of diseases caused by the included antigens (US and Canada only).
A Unique Bond: friends in need A Unique Bond: friends in need After suffering from a stroke, Phil’s connection with Valle helped change his life
Soaring to save lives Soaring to save lives Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
NexGard Spectra NexGard Spectra Prevents heartworm disease and treats and controls hookworm, roundworm, whipworm, and lungworm infestations in dogs and puppies.
2020-Positive-business-momentum-despite-COVID-19-impact 2020-Positive-business-momentum-despite-COVID-19-impact While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Action makes the difference in poultry farms Action makes the difference in poultry farms Farmers, be on the lookout to protect chickens against the ILT virus!
Our-position Our-position Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Mental Health Mental Health Hear the perspectives of people living with cancer on the topic of mental health.
Transforming Science Day Transforming Science Day How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Social Support Social Support People living with cancer share their perspectives on the importance of social support.
Big Little Things in cancer: small things, big impacts Big Little Things in cancer: small things, big impacts Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Prascend Prascend Symptomatic treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s disease).
Advancing health equity for rural doctors in Mexico Advancing health equity for rural doctors in Mexico Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location